BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Inoculation theory (1995) posited that the use of inoculation strategies for these types of campaigns should be utilized to enhance the corporations' credibility and aide in maintaining the existing consumer attitude. This strategy should not be used to change consumer attitudes. Based on the analysis of previous research Burgoon et al. concluded issue/advocacy advertising is most effective for reinforcing support and avoid potential slippage in the attitudes of supporters. Based on previous publications they looked to test three hypotheses. The first was that issue/advocacy advertisements work to inoculate against counterattitudinal attacks. Next, issue/advocacy advertisements work to protect the source credibility. Lastly, conservatives